The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial
The aim of the present study was to evaluate the effect of myo-Inositol administration on oocyte quality, fertilization rate and embryo quality in patients with PCOS during assisted reproductive technology (ART) cycles.
Fifty infertile PCOS patients were randomly designated in two groups. In the study group, patients received daily doses of 4 g myo-Inositol combined with 400 mg folic acid and in the control group patients received only 400 mg folic acid from 1 month before starting the antagonist cycle until the day of ovum pick up. Oocyte and embryo qualities were assessed according to European Society of Human Reproduction and Embryology (ESHRE) guidelines. The gene expression of PGK1, RGS2 and CDC42 as a factor of oocyte quality in granulosa cells was analyzed using real-time RT-PCR. Levels of total antioxidant capacity (TAC) and reactive oxygen species (ROS) were evaluated by chemiluminescence assay in follicular fluid.
The percentage of metaphase II oocyte, fertilization rate and embryo quality significantly improved in the study group (p < 0.05), but the number of retrieved oocytes and follicle count were not statistically different between groups. Furthermore, the gene expression of PGK1, RGS2 and CDC42 was significantly higher in the study group (p < 0.05) but no differences were found between two groups in terms of TAC and ROS levels.
The present study findings suggest that myo-Inositol alters the gene expression in granulosa cells and improves oocyte and embryo quality among PCOS patients undergoing ART.
KeywordsPolycystic ovary syndrome myo-Inositol Oocyte Fertilization Assisted reproductive technology
The authors would like to thank Professor Felice Petraglia (University of Florence, Italy) for his input and guidance in revising our manuscript. This study was financed by Iran University of Medical Science (Grant no. 26493).
A.A.S: substantial contributions to the conception or design, interpretation of data and final approval of the version to be published; A.T: acquisition of data and collecting samples; H.N: acquisition of data; A.A: statistical analysis and interpretation of data; K.S: drafting and english editing of the article; M.M.A: acquisition of data; M.T: acquisition of data; M.A: revision the article critically for the important intellectual contents; F.A: substantial contributions to the conception or design, drafting the article and final approval of the version to be published.
Compliance with ethical standards
Conflict of interest
The authors have no conflict of interest with the subject matter of this manuscript.
- 17.Benner A (1999) Sample size tables for clinical studies. (2nd edn). In: David Machin, Michael JC, Peter MF, Alain PY, Pinol, Blackwell Science Ltd., Oxford, 1997. No. of pages: x+315. Price: £45. ISBN 0-86542-870-0. Stat Med 18(4):494–495Google Scholar
- 22.Papaleo E, et al (2009) Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 91(5):1750–1754Google Scholar
- 24.Unfer V et al (2011) Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study. Gynecol Endocrinol 27(11):857–861CrossRefPubMedGoogle Scholar